Standard
Finding our way through the labyrinth of dementia biomarkers. / Chételat, Gaël; Arbizu, Javier; Barthel, Henryk; Garibotto, Valentina; Lammertsma, Adriaan A; Law, Ian; Morbelli, Silvia; van de Giessen, Elsmarieke; Drzezga, Alexander.
In:
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, No. 8, 2021, p. 2320-2324.
Research output: Contribution to journal › Editorial › Research › peer-review
Harvard
Chételat, G, Arbizu, J, Barthel, H, Garibotto, V, Lammertsma, AA
, Law, I, Morbelli, S, van de Giessen, E & Drzezga, A 2021, '
Finding our way through the labyrinth of dementia biomarkers',
European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 8, pp. 2320-2324.
https://doi.org/10.1007/s00259-021-05301-7APA
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Lammertsma, A. A.
, Law, I., Morbelli, S., van de Giessen, E., & Drzezga, A. (2021).
Finding our way through the labyrinth of dementia biomarkers.
European Journal of Nuclear Medicine and Molecular Imaging,
48(8), 2320-2324.
https://doi.org/10.1007/s00259-021-05301-7Vancouver
Chételat G, Arbizu J, Barthel H, Garibotto V, Lammertsma AA
, Law I et al.
Finding our way through the labyrinth of dementia biomarkers.
European Journal of Nuclear Medicine and Molecular Imaging. 2021;48(8):2320-2324.
https://doi.org/10.1007/s00259-021-05301-7Author
Chételat, Gaël ; Arbizu, Javier ; Barthel, Henryk ; Garibotto, Valentina ; Lammertsma, Adriaan A ; Law, Ian ; Morbelli, Silvia ; van de Giessen, Elsmarieke ; Drzezga, Alexander. / Finding our way through the labyrinth of dementia biomarkers. In: European Journal of Nuclear Medicine and Molecular Imaging. 2021 ; Vol. 48, No. 8. pp. 2320-2324.
Bibtex
@article{f0c6c1be1c114839a57dc4c5374ac1d4,
title = "Finding our way through the labyrinth of dementia biomarkers",
author = "Ga{\"e}l Ch{\'e}telat and Javier Arbizu and Henryk Barthel and Valentina Garibotto and Lammertsma, {Adriaan A} and Ian Law and Silvia Morbelli and {van de Giessen}, Elsmarieke and Alexander Drzezga",
note = "Funding Information: GC has received research support from the EU{\textquoteright}s Horizon 2020 research and innovation programme (grant agreement number 667696), Inserm, Fondation d{\textquoteright}entreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Programme Hospitalier de Recherche Clinique, R{\'e}gion Normandie, Association France Alzheimer et maladies apparent{\'e}es and Fondation Vaincre Alzheimer (all to Inserm), and personal fees from Fondation d{\textquoteright}entreprise MMA des Entrepreneurs du Futur. Funding Information: JA reports grants from General Electric, Piramal, and Lilly-Avid, personal fees from Biogen and Bayer, personal fees and non-financial support from Araclon and Advanced Accelerator Applications, outside of the submitted work. Funding Information: VG is supported by the Swiss National Science Foundation (projects 320030_169876 and 320030_185028), the Velux foundation (project 1123), the Aetas foundation, and the Association Pour la Recherche sur l{\textquoteright}Alzheimer; reports grants from Siemens Healthineers, Life Molecular Imaging, Merck, Cerveau Technologies, Roche, and General Electric Healthcare; and personal fees from Siemens Healthineers and General Electric Healthcare, outside the submitted work. ",
year = "2021",
doi = "10.1007/s00259-021-05301-7",
language = "English",
volume = "48",
pages = "2320--2324",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer",
number = "8",
}
RIS
TY - JOUR
T1 - Finding our way through the labyrinth of dementia biomarkers
AU - Chételat, Gaël
AU - Arbizu, Javier
AU - Barthel, Henryk
AU - Garibotto, Valentina
AU - Lammertsma, Adriaan A
AU - Law, Ian
AU - Morbelli, Silvia
AU - van de Giessen, Elsmarieke
AU - Drzezga, Alexander
N1 - Funding Information:
GC has received research support from the EU’s Horizon 2020 research and innovation programme (grant agreement number 667696), Inserm, Fondation d’entreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Programme Hospitalier de Recherche Clinique, Région Normandie, Association France Alzheimer et maladies apparentées and Fondation Vaincre Alzheimer (all to Inserm), and personal fees from Fondation d’entreprise MMA des Entrepreneurs du Futur.
Funding Information:
JA reports grants from General Electric, Piramal, and Lilly-Avid, personal fees from Biogen and Bayer, personal fees and non-financial support from Araclon and Advanced Accelerator Applications, outside of the submitted work.
Funding Information:
VG is supported by the Swiss National Science Foundation (projects 320030_169876 and 320030_185028), the Velux foundation (project 1123), the Aetas foundation, and the Association Pour la Recherche sur l’Alzheimer; reports grants from Siemens Healthineers, Life Molecular Imaging, Merck, Cerveau Technologies, Roche, and General Electric Healthcare; and personal fees from Siemens Healthineers and General Electric Healthcare, outside the submitted work.
PY - 2021
Y1 - 2021
U2 - 10.1007/s00259-021-05301-7
DO - 10.1007/s00259-021-05301-7
M3 - Editorial
C2 - 33876260
AN - SCOPUS:85111788209
VL - 48
SP - 2320
EP - 2324
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
SN - 1619-7070
IS - 8
ER -
